头孢地尔在 CREDIBLE-CR 和 APEKS-NP 三期随机研究中治疗产金属β-内酰胺酶病原体感染。
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.
机构信息
Infection, Antimicrobials, Modelling, Evolution Research Center, Université de Paris (Paris-Diderot), UMR 1137, Paris, France.
Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bichat, Paris, France.
出版信息
Clin Infect Dis. 2022 Sep 29;75(6):1081-1084. doi: 10.1093/cid/ciac078.
Abstract
In the CREDIBLE-CR and APEKS-NP studies, cefiderocol treatment was effective against gram-negative bacteria producing metallo-B-lactamases; rates of clinical cure (70.8% [17/24]), microbiological eradication (58.3% [14/24]), and day 28 all-cause mortality (12.5% [3/24]) compared favorably with comparators of best-available therapy and high-dose meropenem (40.0% [4/10], 30.0% [3/10], and 50.0% [5/10], respectively).
摘要
在 CREDIBLE-CR 和 APEKS-NP 研究中，头孢地尔治疗产金属β-内酰胺酶的革兰氏阴性菌有效；临床治愈率（70.8%[17/24]）、微生物清除率（58.3%[14/24]）和 28 天全因死亡率（12.5%[3/24]）与最佳可用治疗药物和高剂量美罗培南的对照药物相比具有优势（分别为 40.0%[4/10]、30.0%[3/10]和 50.0%[5/10]）。
相似文献
1
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.头孢地尔在 CREDIBLE-CR 和 APEKS-NP 三期随机研究中治疗产金属β-内酰胺酶病原体感染。
Clin Infect Dis. 2022 Sep 29;75(6):1081-1084. doi: 10.1093/cid/ciac078.
2
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
3
Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies.纳入前瞻性2期和3期随机临床研究的菌血症患者接受头孢地尔治疗的结果。
Infect Dis Ther. 2022 Apr;11(2):853-870. doi: 10.1007/s40121-022-00598-9. Epub 2022 Feb 20.
4
Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.头孢地尔在碳青霉烯类耐药鲍曼不动杆菌感染管理中的前瞻性作用：证据回顾。
Int J Antimicrob Agents. 2023 Aug;62(2):106882. doi: 10.1016/j.ijantimicag.2023.106882. Epub 2023 Jun 8.
5
Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.头孢地尔罗，一种新型的铁载体头孢菌素，用于治疗由多药耐药病原体引起的复杂性尿路感染：临床前和临床药代动力学、药效学、疗效和安全性。
Clin Drug Investig. 2020 Oct;40(10):901-913. doi: 10.1007/s40261-020-00955-x.
6
Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.头孢地尔：一种针对多重耐药革兰氏阴性菌的新型头孢菌素策略。
Clin Infect Dis. 2022 Apr 9;74(7):1303-1312. doi: 10.1093/cid/ciab757.
7
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).头孢地尔罗的体外活性，一种铁载体头孢菌素，针对最近收集的临床相关碳青霉烯类药物不敏感的革兰氏阴性杆菌，包括丝氨酸碳青霉烯酶和金属β-内酰胺酶产生的分离株（SIDERO-WT-2014 研究）。
Int J Antimicrob Agents. 2019 Feb;53(2):177-184. doi: 10.1016/j.ijantimicag.2018.10.007. Epub 2018 Oct 26.
8
[Cefiderocol: a first and novel class of siderophore cephalosporin for Carbapenem-resistant Gram-negative infection].[头孢地尔：用于耐碳青霉烯革兰氏阴性菌感染的首个新型铁载体头孢菌素类药物]
Nihon Yakurigaku Zasshi. 2024;159(5):331-340. doi: 10.1254/fpj.24029.
9
Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials.头孢地尔对来自APEKS-NP和CREDIBLE-CR试验的含OXA-48分离株有效性的证据。
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0110022. doi: 10.1128/aac.01100-22. Epub 2022 Sep 12.
10
New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.新德里金属-β-内酰胺酶促进阴沟肠杆菌对头孢地尔罗耐药的产生。
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0201121. doi: 10.1128/AAC.02011-21. Epub 2021 Dec 6.
引用本文的文献
1
Carbapenem-resistant Gram-negative bacteria exhibiting clinically undetected cefiderocol heteroresistance leads to treatment failure in a murine model of infection.表现出临床未检测到的头孢地尔异质性耐药的耐碳青霉烯革兰氏阴性菌导致感染小鼠模型治疗失败。
Front Microbiol. 2025 May 9;16:1496514. doi: 10.3389/fmicb.2025.1496514. eCollection 2025.
2
Fimsbactin Siderophores From a South African Marine Sponge Symbiont, Marinomonas sp. PE14-40.来自南非海洋海绵共生菌海单胞菌属PE14 - 40的铁载体菌素
Microb Biotechnol. 2025 May;18(5):e70155. doi: 10.1111/1751-7915.70155.
3
Real-Life Cefiderocol Use in Bone and Joint Infection: A French National Cohort.头孢地尔在骨与关节感染中的实际应用：一项法国全国队列研究。
Antibiotics (Basel). 2025 Apr 8;14(4):388. doi: 10.3390/antibiotics14040388.
4
Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another?头孢他啶-阿维巴坦联合氨曲南合剂治疗产VIM型铜绿假单胞菌感染：疗效显著，是否值得再用一种？
J Antimicrob Chemother. 2025 May 2;80(5):1371-1376. doi: 10.1093/jac/dkaf083.
5
In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.新型抗菌剂对金属β-内酰胺酶产生菌的体外活性及耐药机制
Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1041-1068. doi: 10.1007/s10096-025-05080-1. Epub 2025 Mar 10.
6
Carbapenem-Resistant Isolated From a Patient in a Midwestern U.S. Hospital With a History of Indian Travel: Therapeutic Strategies and Clinical Outcomes.从一名有印度旅行史的美国中西部医院患者中分离出的耐碳青霉烯类细菌：治疗策略与临床结果
Case Rep Infect Dis. 2025 Jan 31;2025:8155592. doi: 10.1155/crdi/8155592. eCollection 2025.
7
Carbapenemase Mechanism Testing to Support Treatment, Infection Control, and Public Health: The Role of the Clinical Laboratory.用于支持治疗、感染控制和公共卫生的碳青霉烯酶机制检测：临床实验室的作用
Clin Lab Med. 2025 Mar;45(1):51-61. doi: 10.1016/j.cll.2024.10.006. Epub 2024 Nov 16.
8
National Multicenter Study on the Prevalence of Carbapenemase-Producing Enterobacteriaceae in the Post-COVID-19 Era in Argentina: The RECAPT-AR Study.阿根廷新冠疫情后时代产碳青霉烯酶肠杆菌科细菌流行情况的全国多中心研究：RECAPT-AR研究
Antibiotics (Basel). 2024 Nov 27;13(12):1139. doi: 10.3390/antibiotics13121139.
9
Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.头孢地尔的活性、疗效及新出现的耐药机制研究进展
Curr Issues Mol Biol. 2024 Dec 14;46(12):14132-14153. doi: 10.3390/cimb46120846.
10
Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?英国一个大型中心产碳青霉烯酶肠杆菌科细菌的耐药谱：我们是否已经在失去头孢地尔？
J Antimicrob Chemother. 2025 Jan 3;80(1):59-67. doi: 10.1093/jac/dkae367.
本文引用的文献
1
Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales.产金属β-内酰胺酶肠杆菌科细菌的治疗选择
Infect Drug Resist. 2021 Jan 18;14:125-142. doi: 10.2147/IDR.S246174. eCollection 2021.
2
Treatment of invasive IMP-4 Enterobacter cloacae infection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review.使用头孢他啶/阿维巴坦联合氨曲南治疗移植受者侵袭性 IMP-4 阴沟肠杆菌感染：病例系列和文献复习。
Transpl Infect Dis. 2021 Apr;23(2):e13510. doi: 10.1111/tid.13510. Epub 2020 Dec 4.
3
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).美国传染病学会关于产超广谱β-内酰胺酶肠杆菌科（ESBL-E）、耐碳青霉烯肠杆菌科（CRE）和治疗困难的耐药铜绿假单胞菌（DTR-P. aeruginosa）的治疗指南。
Clin Infect Dis. 2021 Apr 8;72(7):e169-e183. doi: 10.1093/cid/ciaa1478.
4
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.头孢地尔与大剂量延长输注美罗培南治疗革兰阴性菌医院获得性肺炎（APEKS-NP）：一项随机、双盲、3期、非劣效性试验。
Lancet Infect Dis. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3. Epub 2020 Oct 12.
5
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.头孢地尔罗或最佳现有治疗方案治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染的疗效和安全性（CREDIBLE-CR）：一项随机、开放标签、多中心、以病原体为重点、描述性的 3 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
6
Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria.头孢他啶美罗培南复方制剂（cefiderocol）对多重耐药革兰氏阴性菌的活性。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.01582-20.
7
Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline.金属β-内酰胺酶：结构、功能、流行病学、治疗选择和研发管线。
Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.00397-20.
8
Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.头孢他啶-阿维巴坦联合氨曲南治疗产金属β-内酰胺酶肠杆菌科血流感染的疗效。
Clin Infect Dis. 2021 Jun 1;72(11):1871-1878. doi: 10.1093/cid/ciaa586.
9
Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase-Producing During a Regional Outbreak.新德里金属β-内酰胺酶产生菌引起的血流感染在区域暴发期间的临床特征及转归
Open Forum Infect Dis. 2020 Jan 21;7(2):ofaa011. doi: 10.1093/ofid/ofaa011. eCollection 2020 Feb.
10
Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.2012 年至 2015 年，40 个国家临床实验室分离的肠杆菌科和铜绿假单胞菌对头孢他啶-阿维巴坦的活性。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00472-17. Print 2017 Sep.
Zotero 插件